(redirected from CYP19A1)
Also found in: Medical.


 (ə-rō′mə-tāz′, -tāz′)
A key enzyme in the biosynthesis of steroids, especially in the conversion of androgens to estrogens.

[aromat(ic) (because the enzyme increases the number of aromatic carbon rings in the molecular structure of the compounds upon which it acts) + -ase.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


an enzyme that converts testosterone into an oestrogen
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
References in periodicals archive ?
For example, for AOP 7, the text "Aromatase (Cyp19a1) reduction leading to impaired fertility in adult females" was simplified to "aromata cyp19a1 reduct lead impair fertil adult female." This multistep preprocessing consisted of a) dividing an abstract into sentences, b) splitting all sentences into words, c) removing sentences that contain a negation word (never, neither, no, not, did not, hasn't, should not,...) to reduce the risk of false positives, d) deleting stop words (coordinating conjunction, punctuation, most common words) from sentences, and e) stemming the remaining words.
GCs were cultured in a dose-dependent and time-dependent manner with DE-T1, proliferation of GCs was determined by Cell Counting Kit-8 assay, and mRNA levels of insulin-like growth factor 1 receptor (IGF-1R), luteotropic hormone receptor (LHR), follicle-stimulating hormone receptor (FSHR), LHR, and CYP19A1 (aromatase) were determined by quantitative polymerase chain reaction.
After oral exposure of Wistar rats to butylparaben from gestation day 7 to pup day 22, an increased Cyp19a1 (aromatase) expression in testes was observed in all the exposure groups as compared with controls.
Nonstandard abbreviations: StAR, steroidogenic acute regulatory protein; CYP11A1, P450 side-chain cleavage enzyme; CYP11B1, 11[beta] hydroxylase; CYP11B2, aldosterone synthase; CYP17A1, 17 [alpha]-hydroxylase/ 17,20-lyase; CYP21A2,21-hydroxylase; HSD3B2, 3[beta]-hydroxysteroid dehydrogenase type 2; HSD11B1, 11[beta]-hydroxysteroid dehydrogenase type 1; HSD11B2, 11[beta]-hydroxysteroid dehydrogenase type 2; HSD17B, 17 [beta]-hydroxysteroid dehydrogenase; SRD5A2, 5[alpha]-reductase type 2; CYP19A1, P450 Aromatase; SULT2A1, sulfotransferase 2A1.
Promoter hypermethylation and reduced CYP19A1 mRNA and protein levels were evident in PCOS ovaries, suggesting repressed aromatase expression [89].
indicated that epigenetic changes of CYP19A1 (aromatase) gene promoters may lead to poor oocyte and embryo condition by impairing follicular steroidogenesis in patients with endometriosis [96].
The effect of this mutation in ovarian tissue includes deregulation of genes that control gonadal differentiation and cell proliferation, downregulation of key ovarian development genes, upregulation of Sertoli cell differentiation genes, and suppression of CYP19A1 leading to reduced aromatase activity causing androgenic effect [10].
In pigs, miR-378 knockdown increased cumulus expansion and oocyte progression to MII and suppressed aromatase (CYP19A1) expression in cumulus cells.